US EditionPublished • loading... • Updated
Accelerating Organoid Adoption Set to Transform Cancer Drugs
Since the FDA’s April 2025 announcement to phase out required animal testing in favor of human-first preclinical models for monoclonal antibody therapies and other drugs, the adoption of organoids that mimic the structure, function, and cellular complexity of native tissues has been on the rise. These ex vivo systems provide a more physiologically relevant platform for evaluating drug efficacy and toxicity, with the potential to improve clinical…
1 Articles
1 Articles
Accelerating Organoid Adoption Set to Transform Cancer Drugs
Since the FDA’s April 2025 announcement to phase out required animal testing in favor of human-first preclinical models for monoclonal antibody therapies and other drugs, the adoption of organoids that mimic the structure, function, and cellular complexity of native tissues has been on the rise. These ex vivo systems provide a more physiologically relevant platform for evaluating drug efficacy and toxicity, with the potential to improve clinical…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
